selectION Therapeutics focuses on developing innovative peptide-based therapies targeting ion channels, specifically the Kv1.3 potassium channel, which plays a crucial role in the proliferation of effector memory T cells (T EM cells) associated with various autoimmune diseases. Their lead candidate, si-544, selectively inhibits Kv1.3, thereby disrupting the signaling pathways that lead to the chronic activation and proliferation of these pathogenic T EM cells. This targeted approach aims to mitigate harmful immune responses while preserving the overall functionality of the immune system, addressing a significant unmet medical need in conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis.

The company employs a sophisticated screening and development platform to identify and optimize therapeutic peptides derived from the evolutionary adaptations of venomous animals. These peptides exhibit high selectivity and affinity for their targets, allowing for effective modulation of ion channel activity. By leveraging the structural characteristics of these peptides, selectION aims to create best-in-class ion channel blockers that can provide sustained clinical benefits with improved safety profiles compared to traditional therapies that broadly dampen immune responses. The ongoing clinical trials for si-544 further demonstrate the company's commitment to advancing its innovative therapies in the field of autoimmune diseases.

United States

selectION, Inc. is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases and selected cancer indications by targeting autoreactive, chronically activated T cells.

selectION Therapeutics

Company Details